Autek China Inc. Stock

Equities

300595

CNE100002MR0

Medical Equipment, Supplies & Distribution

End-of-day quote Shenzhen S.E. 06:00:00 2024-04-24 pm EDT 5-day change 1st Jan Change
17.67 CNY +2.26% Intraday chart for Autek China Inc. +2.73% -21.74%
Sales 2024 * 2.04B 282M Sales 2025 * 2.48B 343M Capitalization 15.85B 2.19B
Net income 2024 * 774M 107M Net income 2025 * 978M 135M EV / Sales 2024 * 6.95 x
Net cash position 2024 * 1.66B 229M Net cash position 2025 * 2.52B 348M EV / Sales 2025 * 5.37 x
P/E ratio 2024 *
21 x
P/E ratio 2025 *
16.7 x
Employees 3,229
Yield 2024 *
1.35%
Yield 2025 *
1.37%
Free-Float 48.18%
More Fundamentals * Assessed data
Dynamic Chart
Autek China Inc. Announces Profit Distribution Proposal for 2023 CI
Nomura Adjusts Ovctek China’s Price Target to 22.16 Yuan From 25.69 Yuan, Keeps at Neutral MT
Autek China Inc. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Nomura Adjusts Ovctek China's Price Target to 30.19 Yuan From 33.83 Yuan, Keeps at Neutral MT
Autek China Logs Double-Digit Earnings Growth in H1 MT
Autek China Inc. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Autek China Elects Founder as Chairman, General Manager MT
Autek China Inc. signed the share transfer agreement to acquire a 39% stake in Shenzhen Mingmou Ruishi Eye Clinic from Zhao Xiaoting, and Li Xianting for CNY 20.7 million. CI
Autek China Inc. signed the share transfer agreement to acquire a 39% stake in Kunming Shikang Eye Clinic Co., Ltd. from Yunnan Shilikang Enterprise Management Partnership Enterprise (Limited Partnership), Zhang Mingjing, and Ouyang Zhonghua for CNY 58.2 million. CI
Autek China Inc. agreed to acquire an additional 30% stake in Xuancheng Autek Baixiu Medical Devices Co., Ltd. from Huang Guanglu and Liu Jihua for CNY 21.93 million CI
Autek China Inc. agreed to acquire an additional 38.99% stake in Xuancheng Mengdaiwei Medical Devices Co., Ltd. from Huangyan Yulu and Hu Chenying for CNY 21.15 million CI
Autek China Inc. entered into an agreement to acquire additional 39% stake in Quanzhou Autek Optical Technology Co., Ltd. from Zhuang Chaoyang, and Zheng Jing for approximately CNY 30 million. CI
Autek Investment Co., Ltd. entered into an agreement to acquire 39% stake in Suzhou Kangshi Health Eye Information Consulting Co., Ltd. from Yuan Lili and Sun Weiling for CNY 107 million. CI
Autek China Inc. agreed to acquire a 39% stake in Xiantao Jiashi Eye Clinic Co., Ltd. from Wang Tiehan for CNY 17.41 million CI
Autek China Inc. signed the share transfer agreement to acquire an additional 39% stake in Bengbu Autek Optical Equipment Technology Co., Ltd. from Shi Jing for CNY 45 million. CI
More news
1 day+2.26%
1 week+2.73%
Current month-2.86%
1 month-7.05%
3 months-6.66%
6 months-23.51%
Current year-21.74%
More quotes
1 week
16.61
Extreme 16.61
17.84
1 month
16.61
Extreme 16.61
18.99
Current year
15.20
Extreme 15.2
22.65
1 year
15.20
Extreme 15.2
35.03
3 years
15.20
Extreme 15.2
109.70
5 years
13.54
Extreme 13.5397
109.70
10 years
2.33
Extreme 2.3328
109.70
More quotes
Managers TitleAgeSince
Chief Executive Officer 64 00-10-25
Director of Finance/CFO 42 20-05-06
Chief Tech/Sci/R&D Officer 41 18-05-10
Members of the board TitleAgeSince
Director/Board Member 58 20-05-06
Director/Board Member 62 23-04-25
Chief Executive Officer 64 00-10-25
More insiders
Date Price Change Volume
24-04-24 17.67 +2.26% 7 957 394
24-04-24 17.28 -0.58% 6,440,296
24-04-23 17.38 +1.70% 7,650,856
24-04-22 17.09 +1.85% 6,531,300
24-04-19 16.78 -1.87% 6,093,783

End-of-day quote Shenzhen S.E., April 24, 2024

More quotes
Autek China Inc is a China-based company principally engaged in the research and development, production and sales of eye-sight products and the provision of eye-sight services. The Company's main business is non-surgical vision correction. The Company's main products include orthokeratology, general contact lens and care products. Its core product is Dream David orthokeratology. In addition, The Company is also engaged in general glass frame sales business. The Company mainly operates its business in the domestic market.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
17.67 CNY
Average target price
25.17 CNY
Spread / Average Target
+42.43%
Consensus
  1. Stock Market
  2. Equities
  3. 300595 Stock